摘要
采用放射配基结合分析法(RBA)对人乳腺癌组织核基质,胞核及胞浆中的雌激素受体(EmR,EnR,EcR)含量进行测定。所测21例乳腺癌组织中此三种组分的ER含量B_(max)分别为417.54±170.95、147.75±98.32、7.34±5.33fmol/mg蛋白;10例正常乳腺组织EmR、EnR及EcR含量分别为42.33±8.49、25.05±7.81、5.91±2.28fmol/mg蛋白。乳腺癌组织EmR及EnR水平均明显高于正常组织(P<0.01),而EcR则无明显差异(P>0.10);乳腺癌组织EmR/EnR亦明显高于正常组织(P<0.01);13例EcR阳性(≥5fmol/mg蛋白)乳腺癌组织中10例EmR/EnR值较高(≥0.50),占77％。结果提示:核基质是ER的主要定位场所,核内ER尤其是核基质中ER含量测定可能为确定乳腺癌患者的内分泌治疗敏感性提供新的参考指标。
The binding capacities of estrogen receptors in nuclear matrix, nuclei and cytosol of human breast cancer tissue (EmR, EnR, EcR) were estimated with radioligand binding assay of receptors.The average Bmax values of these components in 21 breast cancer specimens are 417.54±170.95,147.75±98.32, 7.34±5.33 fmol/mg protein, andthose in 10 normal breast tissue specimens are 42.33±8.49, 25.05±7.81, 5.91±2.28 fmol/mg protein. Comparing the cancer and normal breast tissues, there is significant difference in Bmax values of EmR and EnR(P<0.01), and no difference in Bmax values of EcR (P>0.10). The EmR/EnR value of 21 breast cancer tissue is 0.65±0.10, and that of 10 normal breast tissue is 0.42±0.04. There is statistical difference between the cancer and normal. 10 of 13(77%) patients, who are EcR-positive, have higher EmR/EnR values (≥0.50). The results suggest that estrogen receptors are mainly located at the nuclear matrix, ER levels in nucleus, especially in nuclear matrix of breast cancer tissue are valuable parameters and may be useful for predicting whetner the patient will be responsible to endocrine therapy.
出处
《核技术》
CAS
CSCD
北大核心
1992年第5期313-317,共5页
Nuclear Techniques
关键词
雌激素受体
内分泌治疗
乳腺癌
RBA
Radioligand binding assay of receptor(RBA) Estrogen receptor Nuclear matrix Endocrine therapy
